Affiliation:
1. From the Blue Cross and Blue Shield Association Technology Evaluation Center, Washington, DC
Abstract
Purpose This systematic review evaluates evidence comparing therapy guided by chemotherapy sensitivity and resistance assays with empiric chemotherapy, emphasizing survival outcomes. Methods Prospective studies were sought comparing patients treated contemporaneously by assay-guided chemotherapy and empiric therapy. An initial MEDLINE search and a search performed by a Working Group of the American Society of Clinical Oncology were reviewed with attention to prespecified study selection criteria. Results This review identified 10 studies meeting selection criteria, plus one retrospective study, using seven different assays. Only two studies randomly assigned patients to assay-guided treatment or empiric treatment. Five of nine nonrandomized studies found significantly higher response rates for patients who received assay-guided therapy compared with those treated empirically. One of the two randomized trials found a significantly higher response rate in the assay-guided group. Four additional studies found response rates favoring assay-guided therapy, but comparisons did not achieve statistical significance. Two nonrandomized studies found overall survival to be significantly improved with assay-guided therapy. One randomized study used a cross-over design that made it difficult to determine whether survival differed between groups, while the other randomized trial found no difference in survival. Six studies provided no comparison of groups on baseline patient characteristics. Only one study reported adverse events data. Conclusion While higher response rates for assay-guided therapy have been observed, differences may be attributable to bias or confounding. Little evidence on survival is available. These results do not establish the relative effectiveness of assay-guided treatment and empiric treatment. Randomized trials are needed.
Publisher
American Society of Clinical Oncology (ASCO)
Reference17 articles.
1. Schrag D, Von Hoff DD, Ajani J, et al: American Society of Clinical Oncology technology assessment: Chemotherapy sensitivity and resistance assays. J Clin Oncol 22:10.1200/JCO.2004.05.065
2. Von Hoff DD, Clark GM, Stogdill BJ, et al: Prospective clinical trial of a human tumor cloning system. Cancer Res 43:1926,1983-1931,
3. A southwest oncology group study on the use of a human tumor cloning assay for predicting response in patients with ovarian cancer
4. Shaw GL, Gazdar AF, Phelps R, et al: Individualized chemotherapy for patients with non-small cell lung cancer determined by prospective identification of neuroendocrine markers and in vitro drug sensitivity testing. Cancer Res 53:5181,1993-5187,
5. Shaw GL, Gazdar AF, Phelps R, et al: Correlation of in vitro drug sensitivity testing results with response to chemotherapy and survival: Comparison of non-small cell lung cancer and small cell lung cancer. J Cell Biochem Suppl 24:173,1996-185,
Cited by
107 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献